Kaleido Biosciences, Inc.
US ˙ OTCPK ˙ US4833471000

Introduction

This page provides a comprehensive analysis of the known insider trading history of Joshua T Brumm. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Joshua T Brumm has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
Chief Executive Officer, Director 268,400
CEO & President, Director 537,998
US:KLDO / Kaleido Biosciences, Inc. See Remarks 80,000
US:VSAR / Versartis, Inc.. COO and CFO 201,269
US:PCYC / Pharmacyclics EVP, Finance 100,000
US:ZLTQ / ZELTIQ Aesthetics, Inc. VP of Corporate Development 26,316
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Joshua T Brumm. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases KLDO / Kaleido Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KLDO / Kaleido Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KLDO / Kaleido Biosciences, Inc. Insider Trades
Insider Sales KLDO / Kaleido Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KLDO / Kaleido Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KLDO / Kaleido Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Joshua T Brumm as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-23 3 CBIO GLYCOMIMETICS INC
Ordinary Shares
268,400
2024-03-12 2024-03-11 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -8,618 537,998 -1.58 25.93 -223,465 13,950,288
2024-03-12 2024-03-11 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -7,769 546,616 -1.40 26.12 -202,926 14,277,610
2024-03-12 2024-03-11 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -9,928 554,385 -1.76 26.10 -259,121 14,469,448
2024-03-12 2024-03-11 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -40,072 564,313 -6.63 25.42 -1,018,630 14,344,836
2024-03-12 2024-03-11 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 50,000 604,385 9.02 5.54 277,000 3,348,293
2024-03-12 2024-03-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -435 554,385 -0.08 27.38 -11,910 15,179,061
2024-03-12 2024-03-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -160,670 554,820 -22.46 26.72 -4,293,102 14,824,790
2024-03-12 2024-03-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -202,238 715,490 -22.04 25.30 -5,116,621 18,101,897
2024-03-12 2024-03-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 209,412 917,728 29.56 5.54 1,160,142 5,084,213
2024-03-12 2024-03-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 153,931 708,316 27.77 5.54 852,778 3,924,071
2024-03-11 2024-03-07 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -9,086 554,385 -1.61 25.85 -234,873 14,330,852
2024-03-01 2024-03-01 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -1,414 563,471 -0.25 29.70 -41,996 16,735,089
2024-03-01 2024-03-01 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -74,090 564,885 -11.60 29.23 -2,165,651 16,511,589
2024-03-01 2024-03-01 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -18,976 638,975 -2.88 28.25 -536,072 18,051,044
2024-03-01 2024-03-01 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 94,480 657,951 16.77 5.54 523,419 3,645,049
2024-03-01 2024-02-29 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -5,520 563,471 -0.97 27.50 -151,800 15,495,452
2024-03-01 2024-02-29 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 5,520 568,991 0.98 5.54 30,581 3,152,210
2024-01-31 2024-01-29 4 DYN Dyne Therapeutics, Inc.
Common Stock
G - Gift -1,500 563,471 -0.27
2024-01-31 2024-01-29 4 DYN Dyne Therapeutics, Inc.
Common Stock
G - Gift -20,000 564,971 -3.42
2024-01-04 2024-01-04 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -38,301 584,971 -6.15 19.05 -729,634 11,143,698
2024-01-04 2024-01-04 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -180,235 623,272 -22.43 18.40 -3,316,324 11,468,205
2024-01-04 2024-01-04 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 200,000 803,507 33.14 5.54 1,108,000 4,451,429
2024-01-04 2024-01-04 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 18,536 603,507 3.17 1.03 19,092 621,612
2024-01-04 2024-01-03 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -16,026 584,971 -2.67 20.50 -328,533 11,991,906
2024-01-04 2024-01-03 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -19,775 600,997 -3.19 19.03 -376,318 11,436,973
2024-01-04 2024-01-03 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -15,382 620,772 -2.42 18.34 -282,106 11,384,958
2024-01-04 2024-01-03 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 51,183 636,154 8.75 1.03 52,718 655,239
2023-12-12 2023-12-11 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -7,585 584,971 -1.28 10.72 -81,311 6,270,889
2023-11-16 2023-11-15 4 DYN Dyne Therapeutics, Inc.
Common Stock
A - Award 358,877 592,556 153.58
2023-09-20 2023-09-18 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -12,032 233,679 -4.90 9.41 -113,221 2,198,919
2023-09-13 2023-09-12 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -7,672 245,711 -3.03 10.41 -79,866 2,557,852
2023-06-12 2023-06-12 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -187,748 253,383 -42.56 12.61 -2,367,502 3,195,160
2023-06-12 2023-06-12 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 171,360 441,131 63.52 1.03 176,501 454,365
2023-06-12 2023-06-09 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -76,582 269,771 -22.11 13.34 -1,021,604 3,598,745
2023-06-12 2023-06-09 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 76,582 346,353 28.39 1.03 78,879 356,744
2023-06-12 2023-06-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -14,189 269,771 -5.00 13.47 -191,126 3,633,815
2023-06-12 2023-06-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -46,811 283,960 -14.15 13.15 -615,565 3,734,074
2023-06-12 2023-06-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 30,088 330,771 10.01 1.03 30,991 340,694
2023-06-12 2023-06-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
G - Gift -1,800 300,683 -0.60
2023-06-12 2023-06-08 4 DYN Dyne Therapeutics, Inc.
Common Stock
G - Gift -20,000 302,483 -6.20
2023-03-15 2023-03-14 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -7,318 322,483 -2.22 13.33 -97,549 4,298,698
2022-12-13 2022-12-12 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -3,322 329,801 -1.00 10.87 -36,110 3,584,937
2022-12-13 2022-12-09 4 DYN Dyne Therapeutics, Inc.
Common Stock
A - Award 144,000 333,123 76.14
2022-10-11 2022-10-10 4 DYN Dyne Therapeutics, Inc.
Common Stock
G - Gift -2,500 189,123 -1.30
2022-10-11 2022-10-10 4 DYN Dyne Therapeutics, Inc.
Common Stock
G - Gift -13,000 191,623 -6.35
2022-10-11 2022-10-10 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -195,800 204,623 -48.90 12.46 -2,439,668 2,549,603
2022-10-11 2022-10-10 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 195,800 400,423 95.69 1.03 201,674 412,436
2022-10-11 2022-10-07 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale -14,200 204,623 -6.49 13.37 -189,854 2,735,810
2022-10-11 2022-10-07 4 DYN Dyne Therapeutics, Inc.
Common Stock
M - Exercise 14,200 218,823 6.94 1.03 14,626 225,388
2022-09-21 2022-09-20 4 DYN Dyne Therapeutics, Inc.
Common Stock
D - Sale to Issuer X -11,836 204,623 -5.47 13.70 -162,153 2,803,335
2022-09-15 2022-09-15 4 DYN Dyne Therapeutics, Inc.
Common Stock
D - Sale to Issuer X -3,480 216,459 -1.58 14.05 -48,894 3,041,249
2022-07-06 2022-07-06 4 DYN Dyne Therapeutics, Inc.
Common Stock
D - Sale to Issuer X -10,963 219,939 -4.75 8.24 -90,335 1,812,297
2022-07-06 2022-07-05 4 DYN Dyne Therapeutics, Inc.
Common Stock
A - Award 24,118 230,902 11.66
2022-06-15 2022-06-14 4 DYN Dyne Therapeutics, Inc.
Common Stock
D - Sale to Issuer X -3,540 206,784 -1.68 4.95 -17,523 1,023,581
2022-03-14 2022-03-11 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -3,384 210,324 -1.58 8.73 -29,542 1,836,129
2021-12-14 2021-12-10 4 DYN Dyne Therapeutics, Inc.
Stock Option (right to buy)
A - Award 177,285 177,285
2021-12-14 2021-12-10 4 DYN Dyne Therapeutics, Inc.
Common Stock
A - Award 118,190 213,708 123.74
2021-10-04 2021-10-01 4 DYN Dyne Therapeutics, Inc.
Common Stock
G - Gift -3,500 95,518 -3.53
2021-09-22 2021-09-21 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -4,584 99,018 -4.42 16.11 -73,848 1,595,180
2021-09-22 2021-09-20 4 DYN Dyne Therapeutics, Inc.
Common Stock
S - Sale X -3,425 103,602 -3.20 15.61 -53,464 1,617,227
2020-09-18 2020-09-17 4 DYN Dyne Therapeutics, Inc.
Common Stock
A - Award 107,027 107,027
2020-09-18 2020-09-16 4 DYN Dyne Therapeutics, Inc.
Stock Option (right to buy)
A - Award 320,781 320,781
2019-03-04 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 80,000 80,000
2017-10-23 2017-10-19 4 VSAR Versartis, Inc.
Common Stock
S - Sale -1,326 201,269 -0.65 2.55 -3,381 513,236
2017-10-10 2017-10-06 4 VSAR Versartis, Inc.
Common Stock
A - Award 97,000 202,595 91.86
2017-06-14 2017-06-13 4 VSAR Versartis, Inc.
Common Stock
S - Sale -1,421 105,595 -1.33 16.05 -22,807 1,694,800
2017-05-17 2017-05-16 4 VSAR Versartis, Inc.
Common Stock
S - Sale -1,263 107,016 -1.17 17.40 -21,976 1,862,078
2017-02-28 2017-02-24 4 VSAR Versartis, Inc.
Stock Option (Right to Buy)
M - Exercise -30,000 122,108 -19.72
2017-02-28 2017-02-24 4 VSAR Versartis, Inc.
Common Stock
S - Sale X -5,653 105,779 -5.07 22.05 -124,649 2,332,427
2017-02-28 2017-02-24 4 VSAR Versartis, Inc.
Common Stock
S - Sale X -6,008 111,432 -5.12 21.46 -128,932 2,391,331
2017-02-28 2017-02-24 4 VSAR Versartis, Inc.
Common Stock
S - Sale X -18,339 117,440 -13.51 20.42 -374,482 2,398,125
2017-02-28 2017-02-24 4 VSAR Versartis, Inc.
Common Stock
M - Exercise 30,000 135,779 28.36 2.53 75,900 343,521
2017-01-31 2017-01-30 4 VSAR Versartis, Inc.
Common Stock
S - Sale -2,945 105,779 -2.71 13.85 -40,794 1,465,251
2017-01-31 2017-01-27 4 VSAR Versartis, Inc.
Stock Option (Right to Buy)
A - Award 65,590 65,590
2017-01-31 2017-01-27 4 VSAR Versartis, Inc.
Common Stock
A - Award 43,900 108,724 67.72
2016-12-29 2016-12-27 4 VSAR Versartis, Inc.
Common Stock
S - Sale -990 64,824 -1.50 15.85 -15,692 1,027,460
2016-12-08 2016-12-07 4 VSAR Versartis, Inc.
Common Stock
S - Sale -3,021 65,814 -4.39 13.25 -40,028 872,036
2016-10-13 2016-10-11 4 VSAR Versartis, Inc.
Common Stock
A - Award 10,000 68,835 17.00
2016-06-17 2016-06-15 4 VSAR Versartis, Inc.
Common Stock
S - Sale -1,448 58,835 -2.40 10.63 -15,392 625,416
2016-05-20 2016-05-20 4 VSAR Versartis, Inc.
Common Stock
S - Sale -1,265 60,283 -2.06 7.87 -9,956 474,427
2016-02-01 2016-01-28 4 VSAR Versartis, Inc.
Stock Option (Right to Buy)
A - Award 83,800 83,800
2016-02-01 2016-01-28 4 VSAR Versartis, Inc.
Common Stock
A - Award 26,000 61,548 73.14
2016-01-04 2015-12-30 4 VSAR Versartis, Inc.
Common Stock
S - Sale -990 35,548 -2.71 12.44 -12,312 442,075
2015-11-13 2015-11-12 4 VSAR Versartis, Inc.
Common Stock
P - Purchase 2,500 36,538 7.34 9.99 24,975 365,015
2015-06-15 2015-06-11 4 VSAR Versartis, Inc.
Common Stock
F - Taxes -1,375 34,038 -3.88 17.28 -23,760 588,177
2015-06-15 2015-06-11 4 VSAR Versartis, Inc.
Common Stock
F - Taxes -1,222 35,413 -3.34 19.90 -24,318 704,719
2014-12-30 2014-12-26 4 VSAR Versartis, Inc.
Stock Option (Right to Buy)
A - Award 24,373 24,373
2014-12-30 2014-12-26 4 VSAR Versartis, Inc.
Common Stock
A - Award 10,445 36,635 39.88
2014-06-13 2014-06-11 4 VSAR Versartis, Inc.
Stock Option (Right to Buy)
A - Award 32,000 32,000
2014-06-13 2014-06-11 4 VSAR Versartis, Inc.
Common Stock
A - Award 15,000 25,000 150.00
2014-04-17 2014-04-15 4 VSAR Versartis, Inc.
Common Stock
A - Award 10,000 10,000
2012-10-29 2012-10-26 4 PCYC PHARMACYCLICS INC
Stock Option (Right to Buy)
A - Award 100,000 100,000
2012-08-13 2012-08-09 4 PCYC PHARMACYCLICS INC
Employee Stock Option (Right to Buy)
A - Award 50,000 50,000
2012-08-13 3 PCYC PHARMACYCLICS INC
No securities owned
0
2012-04-30 2012-02-17 4 ZLTQ Zeltiq Aesthetics Inc
Stock Options (Right to Buy)
A - Award 26,316 26,316
2012-04-30 2012-02-17 4 ZLTQ Zeltiq Aesthetics Inc
Common Stock
A - Award 7,692 7,692
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)